Evidence map›Paper›PMID 35723914›Full record

ArticleJournal of medical Internet research2022

Assessing the Clinical Robustness of Digital Health Startups: Cross-sectional Observational Analysis.

Sean Day, Veeraj Shah, Sari Kaganoff, Shannon Powelson, Simon C Mathews

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. A Narrow Definition of Clinical Robustness.Journal of medical Internet research · 2023
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Sean DayRock Health Inc, San Francisco, CA, United States.ORCID 0000-0002-1985-5776
Veeraj ShahRock Health Inc, San Francisco, CA, United States.ORCID 0000-0003-1872-1028
Sari KaganoffRock Health Inc, San Francisco, CA, United States.ORCID 0000-0002-7193-8341
Shannon PowelsonWhiting School of Engineering, Johns Hopkins University, Baltimore, MD, United States.ORCID 0000-0002-2144-727X
Simon C MathewsDivision of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0003-1961-3360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe digital health sector has experienced rapid growth over the past decade. However, health care technology stakeholders lack a comprehensive understanding of clinical robustness and claims across the industry.

objectiveThis analysis aimed to examine the clinical robustness and public claims made by digital health companies.

methodsA cross-sectional observational analysis was conducted using company data from the Rock Health Digital Health Venture Funding Database, the US Food and Drug Administration, and the US National Library of Medicine. Companies were included if they sell products targeting the prevention, diagnosis, or treatment phases of the care continuum. Clinical robustness was defined using regulatory filings and clinical trials completed by each company. Public claims data included clinical, economic, and engagement claims regarding product outcomes made by each company on its website.

resultsA total of 224 digital health companies with an average age of 7.7 years were included in our cohort. Average clinical robustness was 2.5 (1.8 clinical trials and 0.8 regulatory filings) with a median score of 1. Ninety-eight (44%) companies had a clinical robustness score of 0, while 45 (20%) companies had a clinical robustness score of 5 or more. The average number of public claims was 1.3 (0.5 clinical, 0.4 economic, and 0.4 engagement); the median number of claims was 1. No correlation was observed between clinical robustness and number of clinical claims (r

conclusionsMany digital health companies have a low level of clinical robustness and do not make many claims as measured by regulatory filings, clinical trials, and public data shared online. Companies and customers may benefit from investing in greater clinical validation efforts.

Indexed as

Cross-Sectional StudiesChildData CollectionHumansdigital healthhealth techreal-world evidencesoftware as a medical device (SaaMD)venture capital

Identifiers

PMID35723914
PMCPMC9253972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.